Aurora Spine ( (TSE:ASG) ) has issued an announcement.
Aurora Spine Corporation reported a record revenue of $17.6 million for fiscal year 2024, marking a 21% increase from the previous year. The company’s financial success was driven by a 135% surge in sales of the SiLO-TFX SI joint implant, expansion of its internal sales force, and increased margins. The company also achieved its first annual positive EBITDAC and is poised for further growth with the recent FDA clearance of its new AERO product platform.
Spark’s Take on TSE:ASG Stock
According to Spark, TipRanks’ AI Analyst, TSE:ASG is a Neutral.
Aurora Spine’s overall score reflects its growth potential and recent profitability improvements. However, profitability concerns and valuation issues are significant challenges. The positive technical indicators and strategic leadership changes offer optimism for future growth.
To see Spark’s full report on TSE:ASG stock, click here.
More about Aurora Spine
Aurora Spine Corporation is a leader in spine and interventional spine technology, focusing on improving spinal surgery outcomes. The company offers proprietary products such as the SiLO-TFX system and ZIP product line, targeting the orthopedic, neurosurgical, and pain management markets.
YTD Price Performance: -7.50%
Average Trading Volume: 25,610
Technical Sentiment Signal: Buy
Current Market Cap: C$28.57M
Find detailed analytics on ASG stock on TipRanks’ Stock Analysis page.